DRUG · Unmapped registry intervention
Panobinostat (LBH589), Sorafenib
Find medicine records ·
Find other trials using this name
Clinical trial
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
NCT01005797
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedStudy of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Renal Cancerunresolved
Non Small Cell Lung Cancer (NSCLC)unresolved
Interventions
Sponsors & collaborators
Medical University of South Carolinalead sponsor
Novartis Pharmaceuticalscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01005797 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.